EUVIMEDEUVIMED entdecken
Crossref

Elevated Pleural Fluid IL-9 as a Diagnostic Biomarker for Differentiating Tuberculous from Lung Adenocarcinoma-Associated Malignant Pleural Effusions

Huili Zhou, Shaobing Wang, Qunshan Huang, Tiantian Liu, Guomei Su, Yiyun Zhang, Yusheng Zhang, Jielin Duan, Tianwen Lai

Lung · 16.08.2026 · 204 (1)

DOI: 10.1007/s00408-026-00925-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Lung, online erschienen am 16.08.2026. Verfasst von Huili Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Medicine Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, China. Hauptthemen laut MEDLINE: Pleural Effusion, Malignant, Lung Neoplasms, Adenocarcinoma of Lung, Interleukin-9. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Guangdong Basic and Applied Basic Research Foundation, National Natural Science Foundation of China, Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The differential diagnosis of tuberculous pleural effusion (TPE) and lung adenocarcinoma-associated malignant pleural effusion (LA-MPE) remains challenging. This study aimed to measure interleukin‑9 (IL‑9) levels in pleural fluid and evaluate its diagnostic utility in distinguishing between these two conditions. METHODS: The study enrolled 105 patients with PE (51 TPE and 54 LA-MPE). IL-9 levels in pleural fluid were measured by enzyme-linked immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was employed to identify the optimal cutoff value and assess diagnostic performance, including area under the curve (AUC), sensitivity, and specificity, with adenosine deaminase (ADA) and carcinoembryonic antigen (CEA) as comparators. Internal cross-validation was conducted to examine model robustness, and decision curve analysis was used to evaluate the clinical net benefit of IL-9 alone and in combination with ADA and CEA. RESULTS: IL-9 levels were significantly elevated in TPE compared with LA-MPE (2828.13 vs. 310.55 ng/L, P < 0.001). At a cutoff of 748.47 ng/L, IL-9 distinguished TPE from LA-MPE with a sensitivity of 98.0% and specificity of 92.59%, and an AUC of 0.987 (P < 0.001), exceeding both ADA and CEA. Decision curve analysis showed that, within a threshold probability range of 0.10-0.40, the IL‑9‑based model consistently yielded greater net clinical benefit than conventional markers. Cross-validation further confirmed the robustness of IL-9 for distinguishing TPE from LA-MPE. CONCLUSION: IL-9 demonstrates promising diagnostic performance in differentiating TPE from LA-MPE, with favorable accuracy relative to ADA. It merits further investigation as a potential adjunctive diagnostic tool for pleural effusion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pleural Effusion, MalignantLung NeoplasmsAdenocarcinoma of LungInterleukin-9Tuberculosis, PleuralPleural EffusionHumansFemaleDiagnosis, DifferentialMaleMiddle AgedAdenosine DeaminaseAgedCarcinoembryonic AntigenBiomarkersROC CurveArea Under CurveAdultEnzyme-Linked Immunosorbent AssayPredictive Value of TestsSensitivity and SpecificityAged, 80 and over

Stichwörter der Autor:innen

BiomarkerInterleukin-9Malignant pleural effusionTuberculous pleural effusion

Substanzen

Adenosine DeaminaseCarcinoembryonic AntigenInterleukin-9BiomarkersIL9 protein, human

Autor:innen und Institutionen

  • Respiratory Medicine Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, China.
  • Key Laboratory of Immune Inflammation and Metabolism, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, China.
  • Dongguan Institute of Respiratory Medicine, Guangdong Medical University, Dongguan, 523808, China.
  • Respiratory Medicine Center, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, China. djielin119@163.com.
  • Key Laboratory of Immune Inflammation and Metabolism, The First Dongguan Affiliated Hospital, Guangdong Medical University, Dongguan, 523710, China. djielin119@163.com.
  • Dongguan Institute of Respiratory Medicine, Guangdong Medical University, Dongguan, 523808, China. djielin119@163.com.

Förderung

  • Guangdong Basic and Applied Basic Research Foundation
  • National Natural Science Foundation of China
  • Talent Development Foundation of The First Dongguan Affiliated Hospital of Guangdong Medical University
  • Dongguan Key Laboratory of Immune Inflammation and Metabolism

Zitieren

APA

Zhou, H., Wang, S., Huang, Q., Liu, T., Su, G., Zhang, Y., Zhang, Y., Duan, J., & Lai, T. (2026). Elevated Pleural Fluid IL-9 as a Diagnostic Biomarker for Differentiating Tuberculous from Lung Adenocarcinoma-Associated Malignant Pleural Effusions. Lung, 204(1). https://doi.org/10.1007/s00408-026-00925-8

Vancouver

Zhou H, Wang S, Huang Q, Liu T, Su G, Zhang Y, et al. Elevated Pleural Fluid IL-9 as a Diagnostic Biomarker for Differentiating Tuberculous from Lung Adenocarcinoma-Associated Malignant Pleural Effusions. Lung. 2026;204(1). doi:10.1007/s00408-026-00925-8

BibTeX
@article{Zhou2026,
  author = {Zhou, Huili and Wang, Shaobing and Huang, Qunshan and Liu, Tiantian and Su, Guomei and Zhang, Yiyun and Zhang, Yusheng and Duan, Jielin and Lai, Tianwen},
  title = {Elevated Pleural Fluid IL-9 as a Diagnostic Biomarker for Differentiating Tuberculous from Lung Adenocarcinoma-Associated Malignant Pleural Effusions},
  journal = {Lung},
  year = {2026},
  volume = {204},
  number = {1},
  doi = {10.1007/s00408-026-00925-8}
}
Kostenlos starten →